Kras Inhibitors Market

KRAS Inhibitors Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

The KRAS inhibitors market is expected to reach US$ 197.43 Million by 2032.

The KRAS inhibitors market is expected grow at a CAGR of 5.4% between 2023 to 2032.

The KRAS inhibitors market was estimated to be US$ 116.68 Million in 2022.

The KRAS inhibitors market is driven by several key factors including, growing demand for targeted therapies in oncology, advancements in research and development (R&D) of KRAS inhibitors and rising investments in precision medicine and personalized cancer treatment.

North America has been a significant market for KRAS inhibitors, driven by factors such as advanced healthcare infrastructure, robust research and development activities, and a high prevalence of KRAS-mutated cancers.

The NSCLC segment is likely to be the largest within the indication category for KRAS inhibitors due to the high incidence of KRAS mutations and the demand for targeted therapies in this specific type of cancer.

AstraZeneca (United Kingdom), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (United States), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), Jiangsu Hengrui Medicine Co., Ltd. (China), Johnson & Johnson (United States), Merck KGaA (Germany), Novartis International AG (Switzerland), Pfizer Inc. (United States), Sanofi S.A. (France), Shionogi & Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd. (Israel) among others, are the major players in the KRAS inhibitors market.